1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenstrφm Macroglobulinemia: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies

IBCL - 1172

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenstrφm Macroglobulinemia: A Systematic Review and Meta-Analysis of Randomized and Non-Randomized Studies

Shiwani Keswani

Poster Presenter: Shiwani Keswani

IBCL - 1262

Rosai-Dorfman disease, histiocytosis, radiotherapy, rare diseases, real-world data

Janeth Araujo Cardenas

Poster Presenter: Janeth Araujo Cardenas

Thumbnail for Trends in Non-Hodgkin Lymphoma Incidence, Mortality, and Disease Burden Across Latin America from 1990 to 2023: A Global Burden of Disease Study

IBCL - 1325

Trends in Non-Hodgkin Lymphoma Incidence, Mortality, and Disease Burden Across Latin America from 1990 to 2023: A Global Burden of Disease Study

Renusri Ede

Poster Presenter: Renusri Ede

$Thumbnail for Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)$

IBCL - 1332

Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)

Bradley D. Hunter*

Poster Presenter: Bradley D. Hunter*

Video

Thumbnail for Epidemiology and Hospital Utilization in Peripheral T-Cell Lymphoma: A Retrospective Study From National Inpatient Sample 2023

IBCL - 1337

Epidemiology and Hospital Utilization in Peripheral T-Cell Lymphoma: A Retrospective Study From National Inpatient Sample 2023

Namitha Thotli

Poster Presenter: Namitha Thotli

$Thumbnail for Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab (E+R2) in EPCORE FL-1 vs Real-World Chemoimmunotherapy (CIT) in Relapsed/Refractory Follicular Lymphoma (R/R FL)$

IBCL - 1346

Comparative Effectiveness of Epcoritamab, Lenalidomide, and Rituximab (E+R2) in EPCORE FL-1 vs Real-World Chemoimmunotherapy (CIT) in Relapsed/Refractory Follicular Lymphoma (R/R FL)

Habte Yimer

Poster Presenter: Habte Yimer

$Thumbnail for Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Javier Munoz

Poster Presenter: Javier Munoz

IBCL - 1414

Racial Disparities in Patients Hospitalized With Follicular Lymphoma. A National Inpatient Retrospective Analysis.

Oscar Borja-Montes

Poster Presenter: Oscar Borja-Montes

Thumbnail for Real-World Inpatient Outcomes Associated With Caplacizumab Use in Immune Thrombotic Thrombocytopenic Purpura: A National Inpatient Sample Analysis

IBCL - 1420

Real-World Inpatient Outcomes Associated With Caplacizumab Use in Immune Thrombotic Thrombocytopenic Purpura: A National Inpatient Sample Analysis

Noorain Ahmad

Poster Presenter: Noorain Ahmad